Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 19, 2026, Bernstein initiated coverage of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Outperform rating and a $35 price target, citing potential upside from upcoming clinical readouts in pulmonary hypertension associated with interstitial lung disease and non-infectious uveitis. The firm noted risks around competitive data and launch execution, but said these concerns appear “appropriately discoun ...

Group 1 - The company has experienced a transformative period, focusing on finding and developing impactful drugs through creative methods [4] - The CEO highlighted the successful selection of indications and the development of a robust pipeline, indicating that the efforts are now yielding positive results [4] - The company is optimistic about future prospects, having received a series of positive developments recently [5]

Summary of Roivant Sciences Conference Call Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Date**: March 11, 2026 - **Key Speaker**: Matt Gline, CEO Core Industry Insights - **Transformative Period**: Roivant is experiencing a transformative phase, focusing on drug development and indication selection, with a strong pipeline of products ready for launch and data release [6][8] - **Upcoming Launches**: The company anticipates launching a product for dermatomyositis by the end of September 2026, following the acceptance of their NDA with priority review [7] Key Products and Programs - **Brepocitinib**: - Targeting dermatomyositis, an orphan inflammatory disease with high unmet need. The current patient population in the U.S. is estimated at 40,000, with 75% on first-line therapies [24][25] - The drug is positioned as a significant alternative to existing treatments, particularly for patients currently on high-dose corticosteroids [29] - The launch strategy involves building a patient support organization and a qualified field force to ensure effective adoption [20][31] - **Other Indications**: - **Cutaneous Sarcoidosis**: A pivotal program is set to begin, with promising phase 2 results showing a significant improvement in disease activity [32][34] - **Non-Infectious Uveitis (NIU)**: Data from pivotal studies is expected in the second half of 2026, with a patient population of approximately 70,000 [46][48] Market Context and Competitive Landscape - **Market Opportunity**: The company is focusing on orphan diseases where there is a high unmet need, allowing for a different risk-benefit analysis compared to more common conditions [42] - **Safety Profile**: Brepocitinib, while a JAK inhibitor, is expected to have a favorable safety profile in the context of orphan diseases, where the cost-benefit trade-off is more favorable [44] Future Directions - **Expansion of Indications**: Roivant is exploring additional indications for brepocitinib, including pulmonary sarcoidosis and other severe inflammatory conditions [50][52] - **Immunovant Developments**: The company is also developing FcRn inhibitors, with significant upcoming data releases for conditions like cutaneous lupus and treatment-refractory rheumatoid arthritis [86][88] Financial and Operational Strategy - **R&D Focus**: The company emphasizes a rigorous economic approach to R&D, aiming to maximize value from clinical trials and partnerships [15][16] - **Commercial Strategy**: Roivant plans to leverage learnings from other biotech companies to ensure successful commercial launches, particularly in orphan indications [30][31] Conclusion Roivant Sciences is positioned at a pivotal moment with multiple product launches and data readouts on the horizon, focusing on high unmet needs in orphan diseases. The company's strategic approach to drug development and commercialization aims to capitalize on its innovative pipeline and market opportunities.

Core Insights - Roivant Sciences Ltd. is recognized for its innovative drug development approach, utilizing technology and data to create new medicines through its unique subsidiary model known as "Vants" [1] Group 1: Stock Performance - Cowen & Co. has reiterated a "Buy" rating for Roivant Sciences, indicating strong confidence in the company's growth potential within the healthcare sector [2][5] - Roivant's stock is currently trading at $28.89, reflecting a price increase of approximately 3.73% or $1.04 [3][5] - Over the past year, Roivant's stock has experienced significant volatility, with a high of $29.71 and a low of $8.73, showcasing both risk and reward potential for investors [4] Group 2: Market Metrics - The company's market capitalization is approximately $20.68 billion, with a trading volume of about 4.25 million shares, indicating strong investor interest [4][5] - The stock has shown fluctuations today, with a low of $28.44 and a high of $29.64, reflecting its dynamic nature in the market [3]

Summary of Roivant Sciences Conference Call Company and Industry Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Industry**: Biotechnology, specifically focusing on lipid nanoparticles and mRNA vaccine technology Key Points and Arguments 1. **Settlement Announcement**: Roivant announced a global settlement of $2.25 billion with Moderna, resolving patent litigation related to the COVID-19 vaccine [5][6][10] 2. **Payment Structure**: The settlement includes a $950 million upfront payment to be made in July 2026, and a contingent payment of $1.3 billion based on the outcome of a legal appeal regarding Section 1498 [5][6][11] 3. **Market Share Impact**: The settlement covers Moderna's global market share of COVID vaccines, which is approximately one-third of the total market [6][13] 4. **Historical Context**: This settlement is noted as one of the largest outcomes in patent litigation history, with the potential to be the largest paid-out case among those that would have gone to jury [9][10] 5. **Use of Settlement Proceeds**: Roivant plans to invest the settlement proceeds into its current pipeline and upcoming launches, while also expanding its share buyback program to $1 billion [11][12] 6. **Appeal Process**: The appeal regarding Section 1498 is expected to take 18 to 36 months, with Roivant expressing confidence based on previous favorable rulings [13][24] 7. **Pfizer Litigation**: The company is pursuing a similar case against Pfizer-BioNTech, with the expectation that the outcome of the Moderna case may influence negotiations with Pfizer [31][65] 8. **Brepocitinib Update**: Roivant announced that the NDA for brepocitinib was accepted by the FDA with priority review, with a potential launch by the end of September 2026 [15][57] 9. **Capital Allocation Strategy**: Roivant aims to be efficient in capital allocation, balancing share buybacks with investments in new opportunities and existing programs [70][82] Additional Important Information 1. **Legal Precedents**: The settlement with Moderna sets a legal precedent that may impact the ongoing litigation with Pfizer, although Pfizer is not precluded from making its own validity challenges [76] 2. **Future Royalties**: The settlement is structured as a lump sum that covers all future royalties, eliminating the need for additional payments [51] 3. **Market Preparation for Brepocitinib**: Roivant is actively preparing for the launch of brepocitinib, including building a field force for medical engagement and patient education [78][57] 4. **Investor Relations**: Roivant encourages investors to review SEC filings for more information on forward-looking statements and associated risks [2] This summary encapsulates the critical aspects of Roivant Sciences' recent conference call, highlighting the significant settlement with Moderna, ongoing litigation with Pfizer, and strategic plans for future growth and capital allocation.

Core Viewpoint - Roivant's subsidiary Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna to resolve patent infringement claims related to the use of Genevant's and Arbutus' lipid nanoparticle (LNP) delivery technology in COVID-19 vaccines [1][2][4]. Financial Summary - Moderna will pay $950 million upfront in July 2026 and an additional $1.3 billion contingent on a favorable appellate ruling regarding the applicability of Section 1498 to Genevant's and Arbutus' claims [2][4]. - If the contingent payment is realized, this settlement will be the largest disclosed patent settlement in the pharmaceutical industry and the second largest across any industry [4]. Legal and Patent Implications - The settlement includes a judgment of infringement and no invalidity on four Genevant/Arbutus patents, holding Moderna accountable for its unauthorized use of the technology [4]. - Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications and a covenant not to sue for certain patents and products [2][4]. Company Statements - Genevant's CEO expressed satisfaction with the settlement, emphasizing the importance of their LNP technology in addressing the COVID-19 pandemic [3]. - Arbutus' CEO highlighted the transformative nature of the settlement and the recognition of their scientists' contributions to drug development [3]. Ongoing Litigation - Genevant continues its litigation against Pfizer/BioNTech, whose Comirnaty sales account for approximately two-thirds of global COVID-19 vaccine sales [4]. Shareholder Actions - Roivant's board has approved a $1 billion share repurchase program, which includes a previously authorized $500 million [4][5].

Core Viewpoint - Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna to resolve patent infringement claims related to the unauthorized use of their lipid nanoparticle (LNP) delivery technology in COVID-19 vaccines [1][2]. Settlement Details - Moderna will pay $950 million upfront in July 2026 and an additional $1.3 billion contingent on a favorable appellate ruling regarding the applicability of Section 1498 to Genevant's and Arbutus' claims [2][4]. - The settlement includes a judgment of infringement and no invalidity on four patents held by Genevant and Arbutus [4]. - Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications and a covenant not to sue for certain patents and products [2][4]. Company Statements - Genevant's CEO expressed satisfaction with the settlement, emphasizing the importance of their technology in addressing the pandemic [3]. - Arbutus' CEO highlighted the recognition of their scientists' contributions to drug development and the significance of the settlement for the company [3]. Financial Implications - If the contingent payment is realized, this settlement will be the largest disclosed patent settlement in the pharmaceutical industry and the second largest across all industries [4]. - Arbutus is evaluating a potential return of capital to shareholders in conjunction with the upfront payment [4]. Ongoing Litigation - The litigation against Pfizer/BioNTech regarding the use of Arbutus' patented LNP technology in their COVID-19 vaccines is still ongoing [4].

Core Viewpoint - Roivant's subsidiary Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna to resolve patent infringement claims related to the use of Genevant's and Arbutus' lipid nanoparticle (LNP) delivery technology in COVID-19 vaccines [1][2][4] Financial Summary - Moderna will pay $950 million upfront in July 2026 and an additional $1.3 billion contingent on a favorable appellate ruling regarding patent infringement claims [2][4] - If the contingent payment is realized, this settlement will be the largest disclosed patent settlement in the pharmaceutical industry and the second largest in any industry [4] Legal and Licensing Details - The settlement includes a judgment of infringement and no invalidity on four Genevant/Arbutus patents [4] - Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications, ending all patent-infringement litigation against Moderna related to its COVID-19 vaccines [2][4] Company Statements - Genevant's CEO expressed satisfaction with the settlement, emphasizing the importance of their LNP technology in addressing the COVID-19 pandemic [3] - Arbutus' CEO highlighted the recognition of their scientists' contributions to drug development through the invention of LNP delivery technology [3] Ongoing Litigation - Genevant continues litigation against Pfizer/BioNTech, whose Comirnaty sales account for approximately two-thirds of global COVID-19 mRNA vaccine sales [4]

Core Insights - The 46th Annual TD Cowen Healthcare Conference is being held, featuring discussions on the biotech sector [1] Company Overview - Matt Gline, the CEO of Roivant, is participating in a fireside chat at the conference, indicating the company's engagement with investors and stakeholders [1]

Summary of Roivant Sciences FY Conference Call (March 03, 2026) Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: 46th Annual TD Cowen Healthcare Conference Key Points PDUFA Date and Drug Launch - The PDUFA date for Roivant's therapy is set for the third quarter of 2026, with a planned launch by the end of September 2026 [6][8] - The company received a priority review from the FDA, indicating confidence in the therapy's data quality [10] Market Expectations and Physician Feedback - Surveys indicate that physicians expect a 30% market share for the new therapy, which aligns with historical accuracy of such surveys [12][13] - There is significant excitement among physicians regarding the potential to reduce steroid burden for patients [16] Treatment Landscape - Approximately 75% of the 40,000 patients tracked are currently managed with DMARDs and oral steroids, while 25% are on IVIG or off-label treatments [17][18] - The new therapy is expected to attract patients dissatisfied with current treatments, particularly those with high steroid burdens [19][20] Efficacy and Labeling - The therapy is anticipated to have a broad indication for dermatomyositis, aiming to serve a wide patient population [13][14] - The study included a steroid taper, and the company plans to provide extensive information on managing steroid reduction [15] Clinical Trials and Data - The NEPTUNE study showed a 29% relapse rate at the 45 mg dose, significantly better than Humira's 62% [23] - The CLARITY studies are designed to mirror NEPTUNE, with a focus on steroid tapering [24][26] Future Studies and Approvals - The company is preparing for phase 3 studies based on positive phase 2 data, with discussions ongoing with the FDA regarding trial design [48][49] - The goal is to maintain consistency with successful phase 2 data in future studies [49] Mosliciguat and Other Programs - Mosliciguat is being studied for pulmonary hypertension with promising phase 1 data showing significant peripheral vascular resistance reduction [61] - The phase 2b PHOCUS study is expected to read out data in the second half of the year, focusing on PVR and six-minute walk metrics [62][64] IMVT-1402 for Graves' Disease - Data from the FORWARD studies for Graves' disease is expected next year, with a focus on controlling refractory patients [82][83] - The therapy aims to provide a new treatment option for patients who are currently uncontrolled on antithyroid drugs (ATDs) [82][84] Legal Matters - Ongoing litigation with Moderna regarding intellectual property, with the company feeling confident about its position [92][93] Additional Insights - The company is focused on addressing the needs of patients who are currently dissatisfied with existing therapies, particularly in underdeveloped treatment landscapes [20][73] - There is a strong emphasis on the importance of patient comfort and the potential for new therapies to improve quality of life [70][72]